CD63 and neoplasm: In addition, the amounts of PD-L1, but not CD63, in the EVs from the plasma of the mice treated with MAC alone or with combination of MAC and anti-PD-L1 antibody were significantly decreased, compared to the vehicle or anti-PD-L1 alone group (Figure S8C), suggesting that MAC inhibited tumor-derived EV PD-L1 in vivo.